Aengus Ó Snodaigh (Dublin South Central, Sinn Fein)
Link to this: Individually | In context

Question 12: To ask the Minister for Defence that, contrary to military authorities' claims that alternative drugs were available for the treatment of malaria and that Lariam was not the only one, his views on whether the military authorities' continue to issue Lariam because it is cheaper than other more effective anti-malaria drugs [37996/10]

Tommy Broughan (Dublin North East, Independent)
Link to this: Individually | In context

Question 22: To ask the Minister for Defence the number of EU member states who still prescribe the anti-malaria drug Lariam for their troops who are serving in areas where they will be exposed to the danger of malaria; and if he will make a statement on the matter. [38086/10]

Tony Killeen (Clare, Fianna Fail)
Link to this: Individually | In context

I propose to take Questions Nos. 12 and 22 together.

At the outset, let me state categorically that cost is not the basis for determining the prescribing of Lariam to Defence Forces personnel.

I am advised by the military authorities that there are four main chemo prophylactic anti-malaria agents available to the Defence Forces. These are Lariam, Chloroquine, Malarone and Doxycycline. Lariam is considered an effective anti-malaria drugs for the type of malaria our troops were exposed to in Chad and Central African Republic. Troops being administered the drug are informed of its effects and its use is very closely monitored by the military medical authorities. In addition, there is intensive medical screening of troops before Lariam is prescribed along with in theatre monitoring and post mission assessment.

Lariam is an Irish Medicines Board approved drug with a weekly dosing regime. From a compliance viewpoint, it is easier to manage a weekly dosage than a daily medication. While the main recognised disadvantage of Lariam is its side effect profile, I understand that the Irish Medicines Board remains of the view that the benefit/risk profile for the product remains acceptable. The Irish Medicines Board continues to review the safety of this and all medicines on an ongoing basis and updates the product information as appropriate.